KRAS and lung cancer: Taken together, our results indicated that by increasing DEPTOR levels, Ube2c deletion inactivated mTORC signaling to inhibit KrasG12D-induced lung tumorigenesis, and suggested that UBE2C could be an effective therapeutic target for management of lung cancer associated with Kras mutation.